Literature DB >> 23636176

Changes in dialysis treatment modalities during institution of flat rate reimbursement and quality assurance programs.

Werner Kleophas1, Angelo Karaboyas, Yun Li, Juergen Bommer, Helmut Reichel, Andreas Walter, Andrea Icks, Lars C Rump, Ronald L Pisoni, Bruce M Robinson, Friedrich K Port.   

Abstract

Dialysis procedure rates in Germany were changed in 2002 from per-session to weekly flat rate payments, and quality assurance was introduced in 2009 with defined treatment targets for spKt/V, dialysis frequency, treatment time, and hemoglobin. In order to understand trends in treatment parameters before and after the introduction of these changes, we analyzed data from 407 to 618 prevalent patients each year (hemodialysis over 90 days) in 14-21 centers in cross-sections of the Dialysis Outcomes and Practice Patterns Study (phases 1-4, 1998-2011). Descriptive statistics were used to report differences over time in the four quality assurance parameters along with erythropoietin-stimulating agent (ESA) and intravenous iron doses. Time trends were analyzed using linear mixed models adjusted for patient demographics and comorbidities. The proportion of patients with short treatment times (less than 4 h) and low spKt/V (below 1.2) improved throughout the study and was lowest after implementation of quality assurance. Hemoglobin levels have increased since 1998 and remained consistent since 2005, with only 8-10% of patients below 10 g/dl. About 90% of patients were prescribed ESAs, with the dose declining since peaking in 2006. Intravenous iron use was highest in 2011. Hence, trends to improve quality metrics for hemodialysis have been established in Germany even after introduction of flat rate reimbursement. Thus, analysis of facility practice patterns is needed to maintain quality of care in a cost-containment environment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23636176     DOI: 10.1038/ki.2013.143

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  5 in total

Review 1.  Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices.

Authors:  Bruce M Robinson; Tadao Akizawa; Kitty J Jager; Peter G Kerr; Rajiv Saran; Ronald L Pisoni
Journal:  Lancet       Date:  2016-05-22       Impact factor: 79.321

2.  International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study.

Authors:  Douglas S Fuller; Brian A Bieber; Ronald L Pisoni; Yun Li; Hal Morgenstern; Tadao Akizawa; Stefan H Jacobson; Francesco Locatelli; Friedrich K Port; Bruce M Robinson
Journal:  J Am Soc Nephrol       Date:  2015-11-18       Impact factor: 10.121

3.  Implementation of a quality and safety checklist for haemodialysis sessions.

Authors:  Daniele Marcelli; Antero Matos; Francisco Sousa; Ricardo Peralta; João Fazendeiro; Angel Porra; Victor Moscardo; Maria Teresa Parisotto; Andrea Stopper; Bernard Canaud
Journal:  Clin Kidney J       Date:  2015-01-12

4.  Comparative changes in treatment practices and clinical outcomes following implementation of a prospective payment system: the STEPPS study.

Authors:  Keri L Monda; Parveen Nedra Joseph; Peter J Neumann; Brian D Bradbury; Robert J Rubin
Journal:  BMC Nephrol       Date:  2015-05-01       Impact factor: 2.388

5.  Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005-13.

Authors:  Kate Birnie; Fergus Caskey; Yoav Ben-Shlomo; Jonathan A C Sterne; Julie Gilg; Dorothea Nitsch; Charles Tomson
Journal:  Nephrol Dial Transplant       Date:  2017-04-01       Impact factor: 5.992

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.